Horse Mushroom

Metadata

Regulatory Status

European Union

• Food status: Long and well-established history of consumption as a wild edible mushroom across Europe. One of the most commonly collected wild Agaricus species in Britain, Ireland, France, Germany, and Scandinavia.
• Market presence: Sold fresh in seasonal wild mushroom markets but not commercially cultivated. Dwarfed in the marketplace by the related A. bisporus (button/cremini/portobello), which dominates global commercial mushroom production.
• No novel food determination required for whole mushroom consumption.

United States

• Food status: Known wild edible mushroom, though less commonly foraged than in Europe. Found in grasslands and parks across North America.
• FDA GRAS status: No specific GRAS determination for A. arvensis. The related A. bisporus is GRAS.
• Dietary supplement: Not marketed as a dietary supplement.

China and Japan

• Not listed in the Chinese Pharmacopoeia or Japanese Pharmacopoeia. Not a significant species in East Asian cuisine or traditional medicine.

Agaritine Regulatory Context

• European Food Safety Authority (EFSA): EFSA has reviewed the agaritine content of Agaricus mushrooms. The EFSA CONTAM Panel concluded in 2022 that genotoxicity of agaritine and its metabolite 4-(hydroxymethyl)phenylhydrazine (HMPH) could not be excluded, but that based on exposure assessment, the risk from normal dietary consumption of cultivated Agaricus mushrooms is low. Cooking reduces agaritine content by 50-90%, further mitigating potential risk.
• IARC classification: Agaritine is not individually classified by IARC. The hydrazine class in general has carcinogenic potential, but dietary exposure from mushroom consumption is considered very low risk.

Conditions & Indications

Primary: Antioxidant Activity (Preclinical Evidence)

• Phenolic antioxidant capacity: A. arvensis extracts demonstrate strong radical scavenging activity in DPPH, ABTS, and ferric reducing power assays. The total phenolic content is among the higher values reported for wild Agaricus species, with gallic acid and catechin identified as the major contributors.
• Tocopherol contribution: Significant alpha-tocopherol and gamma-tocopherol content provides lipophilic antioxidant defense, contributing to the overall antioxidant capacity of the mushroom. Alpha-tocopherol is the most biologically active form of vitamin E.
• Ergosterol content: The high ergosterol content represents both provitamin D2 potential and a contribution to membrane antioxidant defense.

Secondary: Antimicrobial Activity (Preclinical Evidence)

• Antibacterial effects: Extracts demonstrate inhibitory activity against gram-positive bacteria (Staphylococcus aureus, Bacillus cereus, Bacillus subtilis) and gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa) in disc diffusion and microdilution assays.
• Antifungal activity: Some studies report modest antifungal activity against Candida albicans and Aspergillus species.

Emerging/Preclinical

• Immunomodulatory potential: By analogy with the well-studied A. blazei (Agaricus blazei Murrill / A. subrufescens), the polysaccharide fraction of A. arvensis likely possesses immunomodulatory properties, though direct evidence for this species is limited. [NEEDS-RESEARCH]
• Anticancer screening: Limited cytotoxicity screening has shown modest antiproliferative effects of A. arvensis extracts against cancer cell lines, but systematic investigation is lacking. [NEEDS-RESEARCH]
• Vitamin D2 potential: Like A. bisporus, ergosterol in A. arvensis can be converted to vitamin D2 by UV-B radiation. Post-harvest UV treatment of mushrooms to enhance vitamin D2 content has been demonstrated for A. bisporus and would likely be effective for A. arvensis as well. [NEEDS-RESEARCH]
• Nutritional significance: A. arvensis is a nutritionally valuable wild food providing protein (2-4% fresh weight), dietary fiber, B vitamins (niacin, riboflavin, pantothenic acid), potassium, phosphorus, selenium, and essential amino acids.

Mechanism of Action

Primary Mechanisms

1. Phenolic compound radical scavenging: Gallic acid, catechin, and protocatechuic acid contribute to antioxidant capacity through multiple mechanisms: direct hydrogen atom transfer to free radicals, single electron transfer, chelation of pro-oxidant transition metals (particularly iron and copper), and inhibition of pro-oxidant enzymes. Gallic acid is additionally known to suppress NF-kB activation and COX-2 expression, conferring anti-inflammatory activity. Catechin, a flavan-3-ol, provides potent radical scavenging through the catechol group on the B-ring and can also inhibit lipid peroxidation in cell membranes.

2. Tocopherol lipophilic antioxidant defense: Alpha-tocopherol and gamma-tocopherol function as chain-breaking antioxidants in lipid membranes and lipoproteins, scavenging lipid peroxyl radicals to terminate lipid peroxidation chain reactions. The recycling of tocopheroxyl radicals back to active tocopherol by ascorbic acid (vitamin C) and ubiquinol creates a cooperative antioxidant network. Gamma-tocopherol is additionally effective at trapping nitrogen-based free radicals (peroxynitrite, nitrogen dioxide), providing a complementary protective spectrum to alpha-tocopherol.

3. Beta-glucan immunomodulation: Polysaccharides from A. arvensis, consistent with the beta-glucan content documented across the Agaricus genus, are expected to activate innate immune cells through pattern recognition receptors (dectin-1, TLR-2, complement receptor 3). This mechanism is well-established for the closely related A. blazei and A. bisporus and likely extends to A. arvensis, though direct experimental confirmation is limited.

Secondary Mechanisms

• Ergosterol provitamin D2 activity: Ergosterol is converted to vitamin D2 upon UV-B exposure, with subsequent hepatic and renal hydroxylation producing the active hormone 1,25-dihydroxyvitamin D2, which acts through the vitamin D receptor to regulate calcium homeostasis, immune function, and cell proliferation.
• Lectin biological activity: Lectins from Agaricus species are carbohydrate-binding proteins with diverse biological effects including hemagglutination, mitogenic activity on lymphocytes, and in some cases antiproliferative activity against tumor cell lines. The specific lectin profile of A. arvensis is not well characterized compared to A. bisporus.
• Fatty acid metabolism: The predominant unsaturated fatty acids (linoleic acid, oleic acid) contribute to the nutritional value but also influence inflammation through their roles as precursors to eicosanoids (linoleic acid to arachidonic acid pathway) and through direct cell membrane effects.

Clinical Evidence Summary

No human clinical trials have been published for Agaricus arvensis for any therapeutic indication. The pharmacological evidence base consists of analytical studies and in vitro screening assays. Much of the applicable evidence comes from research on the closely related A. bisporus and the medicinal A. blazei (A. subrufescens).

Key Studies

Evidence Limitations

• No clinical trials: The entire evidence base for A. arvensis specifically is preclinical.
• Reliance on genus-level extrapolation: Much of the pharmacological understanding of A. arvensis is inferred from studies on A. bisporus and A. blazei. While the genus-level similarities are strong, species-specific differences in bioactive compound concentrations and biological activities exist.
• Limited study volume: The total number of studies specifically addressing A. arvensis pharmacology is small, reflecting its status as a wild-collected species overshadowed in research attention by the commercially cultivated A. bisporus.
• Geographic chemical variation: Bioactive compound profiles vary with geographic origin, soil type, and season.
• Cadmium contamination variable: Heavy metal content is highly site-dependent, making generalizations about safety at the species level problematic.
• Agaritine debate unresolved: The long-running scientific debate about whether dietary agaritine exposure from Agaricus mushrooms poses a meaningful cancer risk remains unresolved, though the consensus has shifted toward very low risk at normal dietary intake levels with cooking.

Safety Profile

General Assessment

A. arvensis has been consumed as a prized wild edible mushroom across Europe for centuries with an excellent safety record at culinary consumption levels. It is one of the most widely collected wild Agaricus species in temperate regions. The two primary safety considerations are agaritine content (shared with all Agaricus species) and cadmium bioaccumulation potential.

Agaritine Content and the Carcinogenicity Question

• What is agaritine? Agaritine (beta-N-(gamma-L(+)-glutamyl)-4-hydroxymethylphenylhydrazine) is a naturally occurring hydrazine derivative found in all Agaricus species. It is enzymatically converted to 4-(hydroxymethyl)phenylhydrazine (HMPH) and subsequently to 4-(hydroxymethyl)benzenediazonium ion, a reactive diazonium compound that can form DNA adducts.
• Evidence for concern: HMPH and its diazonium metabolite are mutagenic in Ames test bacterial systems and in mammalian cell culture. Lifetime feeding studies with very high doses of agaritine in mice showed a modest increase in lung and blood vessel tumors.
• Evidence against concern: Epidemiological studies have not found an association between mushroom consumption and cancer risk. Many studies find an inverse association (mushroom consumption associated with reduced cancer risk). The EFSA concluded that while genotoxicity cannot be excluded, the margin of exposure from normal dietary consumption is reassuring. Agaritine is reduced by 50-90% through cooking (especially boiling) and by 25-50% through storage at refrigerator temperature over several days.
• Practical significance: At normal dietary intake (100-200 g of cooked Agaricus mushrooms per meal, consumed a few times per week), the agaritine exposure is considered very low risk by most food safety authorities. Cooking is strongly recommended for all Agaricus species.

Cadmium Bioaccumulation

• Documented concern: A. arvensis is known to be an effective bioaccumulator of cadmium from soil, with fruiting body cadmium concentrations sometimes exceeding EU regulatory limits (0.20 mg/kg wet weight for cultivated mushrooms, 1.0 mg/kg for wild mushrooms). Cadmium concentrations in A. arvensis fruiting bodies from contaminated sites have been reported at 1-50 mg/kg dry weight.
• Site dependency: Cadmium accumulation is strongly dependent on soil cadmium levels. Specimens from uncontaminated rural grasslands typically have much lower cadmium levels than those from urban parks, roadsides, or former industrial sites.
• Health implications: Chronic cadmium exposure is associated with renal tubular dysfunction, osteoporosis, and lung cancer. Regular consumption of wild A. arvensis from contaminated sites could contribute to problematic cadmium intake.
• Recommendation: Avoid harvesting A. arvensis from urban environments, roadsides, or sites with known soil contamination. For regular consumers of wild Agaricus mushrooms, occasional cadmium testing of specimens from favored harvesting sites is advisable.

Contraindications

• Mushroom allergy: Individuals with known allergy to Agaricus mushrooms should avoid consumption.
• Contaminated harvest sites: Due to cadmium bioaccumulation potential.
• Identification caution: Must be carefully distinguished from the toxic A. xanthodermus (yellow-staining mushroom), which causes gastrointestinal poisoning. Key distinguishing features: A. arvensis stains yellow but smells of anise, while A. xanthodermus stains bright chrome yellow at the cap base and smells of phenol/ink when the flesh is cut. Young A. arvensis buttons can also resemble Amanita species before the cap expands.

Drug Interactions

• No documented drug interactions at culinary consumption levels.

Side Effects

• Common: None documented at normal culinary consumption levels of cooked specimens.
• Uncommon: Gastrointestinal discomfort from undercooked specimens.
• Rare: Allergic reactions in fungal-sensitive individuals.

Toxicology

• No acute toxicity from A. arvensis consumption has been documented.
• The agaritine question represents a chronic, low-level concern rather than an acute toxicity risk.
• Cadmium bioaccumulation is the most practically significant safety issue for regular consumers.

Clinical Dosage

No Established Therapeutic Dosage

No human clinical trials have been conducted with A. arvensis, so no evidence-based therapeutic dosage recommendations exist.

Culinary Consumption

• Fresh fruiting body: Young specimens with closed or recently opened caps are preferred. Typical culinary portion is 100-200 g fresh weight per meal.
• Preparation: Should always be cooked (sauteed, grilled, added to soups, or baked). Cooking reduces agaritine content by 50-90% and improves digestibility. The anise-like aroma (from benzaldehyde and related compounds) intensifies with gentle cooking.
• Flavor profile: Nutty, anise-scented flavor, generally considered milder and more refined than A. bisporus. Flesh is white, not discoloring when cut (unlike A. xanthodermus).
• Drying: Can be dried for long-term storage. Dried A. arvensis concentrates flavors and bioactive compounds per gram, though vitamin C is largely lost.

Nutritional Value per 100 g Fresh Weight (Approximate)

• Energy: 25-35 kcal
• Protein: 2.5-4.0 g
• Fat: 0.3-0.5 g
• Carbohydrates: 3-5 g
• Dietary fiber: 2-3 g
• Potassium: 350-500 mg
• Phosphorus: 100-150 mg
• Selenium: 5-20 micrograms (highly variable with soil)
• Niacin (B3): 3-5 mg
• Riboflavin (B2): 0.3-0.5 mg

Comparison with A. bisporus

As a wild relative of the world’s most commercially cultivated mushroom (A. bisporus), A. arvensis offers similar nutritional value with a more complex flavor profile. Foragers who regularly collect A. arvensis gain access to a fresh, unprocessed source of Agaricus-type nutrition without the concerns about long storage or processing that apply to commercial mushrooms. The anise aroma (absent in A. bisporus) reflects a distinctive volatile compound profile that may include additional bioactive aromatic compounds.

Sources

• Barros L, Duenas M, Ferreira ICFR, Baptista P, Santos-Buelga C. Phenolic acids determination by HPLC-DAD-ESI/MS in sixteen different Portuguese wild mushrooms species. Food Chem Toxicol. 2009;47(6):1076-1079
• Ozen T, Darcan C, Aktop O, Turkekul I. Screening of antioxidant, antimicrobial activities and chemical contents of edible mushrooms wildly grown in the Black Sea region of Turkey. Comb Chem High Throughput Screen. 2011;14(2):72-84
• Kalac P. A review of chemical composition and nutritional value of wild-growing and cultivated mushrooms. J Sci Food Agric. 2013;93(2):209-218
• Schulzova V, Hajslova J, Peroutka R, Gry J, Andersson HC. Influence of storage and household processing on the agaritine content of the cultivated Agaricus mushroom. Food Addit Contam. 2002;19(9):853-862
• Vetter J. Arsenic and cadmium content of some common wild mushrooms. Acta Aliment. 2004;33(3):279-288
• Ferreira ICFR, Barros L, Abreu RMV. Antioxidants in wild mushrooms. Curr Med Chem. 2009;16(12):1543-1560
• Shephard SE, Gunz D, Schlatter C. Genotoxicity of agaritine in the lacI transgenic mouse mutation assay: evaluation of the health risk of mushroom consumption. Food Chem Toxicol. 1995;33(4):257-264
• Roupas P, Keogh J, Noakes M, Margetts C, Taylor P. The role of edible mushrooms in health: evaluation of the evidence. J Funct Foods. 2012;4(4):687-709
• European Food Safety Authority CONTAM Panel. Risk assessment of agaritine. EFSA J. 2023;21(8):e08177
• Melgar MJ, Alonso J, Garcia MA. Cadmium in edible mushrooms from NW Spain: bioconcentration factors and consumer health implications. Food Chem Toxicol. 2016;88:13-20
• Falandysz J, Borovicka J. Macro and trace mineral constituents and radionuclides in mushrooms: health benefits and risks. Appl Microbiol Biotechnol. 2013;97(2):477-501
• Mattila P, Konko K, Eurola M, Pihlava JM, Astola J, Vahteristo L, et al. Contents of vitamins, mineral elements, and some phenolic compounds in cultivated mushrooms. J Agric Food Chem. 2001;49(5):2343-2348

Connections

• Agaricus genus medicinal network: A. arvensis belongs to the same genus as Button Mushroom (A. bisporus), the world’s most commercially cultivated mushroom, and Agaricus blazei (A. subrufescens), a mushroom with well-established immunomodulatory research. The genus-level pharmacological similarities (beta-glucan immunomodulation, phenolic antioxidant activity, agaritine content) suggest that research findings from the better-studied species are partially applicable to A. arvensis, though species-specific validation is lacking.
• Wild Agaricus foraging: A. arvensis is one of several edible Agaricus species encountered by European foragers. Correct identification is essential to distinguish it from the toxic A. xanthodermus, which shares similar habitats but causes gastrointestinal poisoning. The anise scent of A. arvensis versus the chemical/ink/phenol scent of A. xanthodermus is the most reliable field distinction.
• Heavy metal bioaccumulation: The cadmium bioaccumulation capacity of A. arvensis is a concern shared with other saprotrophic fungi that grow in rich soils. This is relevant to all wild mushroom foragers and is a consideration in interpreting the safety profiles of wild-harvested species throughout this reference.
• Antioxidant wild foods: Within the antioxidant-longevity category of this reference, A. arvensis contributes a phenolic and tocopherol-based antioxidant profile that complements the ergothioneine-rich profile of Porcini and the vitamin C-rich profile of Beefsteak Fungus.